Pharvaris NV (PHVS)
38.65
+0.91
(+2.41%)
USD |
NASDAQ |
Sep 10, 11:46
Pharvaris Debt to Equity Ratio : 0.0022 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0022 |
| March 31, 2026 | 0.0031 |
| December 31, 2025 | 0.0029 |
| September 30, 2025 | 0.0019 |
| June 30, 2025 | 0.0034 |
| March 31, 2025 | 0.0033 |
| December 31, 2024 | 0.0032 |
| September 30, 2024 | 0.0004 |
| June 30, 2024 | 0.0004 |
| March 31, 2024 | 0.0005 |
| December 31, 2023 | 0.0006 |
| September 30, 2023 | 0.0019 |
| June 30, 2023 | 0.0019 |
| March 31, 2023 | 0.003 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0029 |
| September 30, 2022 | 0.0011 |
| June 30, 2022 | 0.0011 |
| March 31, 2022 | 0.0012 |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Novartis AG | 1.180 |
| BioAge Labs, Inc. | 0.0076 |
| AstraZeneca PLC | 0.7166 |
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 375.77M |
| Total Liabilities (Quarterly) | 31.85M |
| Shareholders Equity (Quarterly) | 343.92M |
| Current Ratio | 11.94 |
| Net Debt Paydown Yield | 0.00% |